home / stock / mdnaf / mdnaf quote
Last: | $1.83 |
---|---|
Change Percent: | 0.55% |
Open: | $1.86 |
Close: | $1.82 |
High: | $1.94 |
Low: | $1.808 |
Volume: | 59,537 |
Last Trade Date Time: | 04/29/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.83 | $1.86 | $1.82 | $1.94 | $1.808 | 59,537 | 04-29-2024 |
$1.82 | $1.493 | $1.82 | $1.92 | $1.493 | 577,695 | 04-26-2024 |
$1.4 | $1.34 | $1.4 | $1.47 | $1.336 | 119,692 | 04-25-2024 |
$1.39 | $1.148 | $1.39 | $1.3999 | $1.148 | 449,264 | 04-24-2024 |
$1.14 | $1.12 | $1.14 | $1.165 | $1.11 | 58,363 | 04-23-2024 |
$1.106 | $1.19 | $1.106 | $1.19 | $1.0942 | 90,235 | 04-22-2024 |
$1.19 | $1.2499 | $1.19 | $1.26 | $1.14 | 71,579 | 04-19-2024 |
$1.24 | $1.25 | $1.24 | $1.29 | $1.24 | 67,251 | 04-18-2024 |
$1.27 | $1.3328 | $1.27 | $1.3686 | $1.27 | 137,151 | 04-17-2024 |
$1.34 | $1.36 | $1.34 | $1.41 | $1.34 | 62,750 | 04-16-2024 |
$1.38 | $1.39 | $1.38 | $1.455 | $1.35 | 80,190 | 04-15-2024 |
$1.42 | $1.44 | $1.42 | $1.46 | $1.36 | 205,659 | 04-12-2024 |
$1.41 | $1.4684 | $1.41 | $1.47 | $1.3197 | 114,172 | 04-11-2024 |
$1.45 | $1.29 | $1.45 | $1.466 | $1.18 | 419,006 | 04-10-2024 |
$1.09 | $1.26 | $1.09 | $1.26 | $1.0306 | 175,373 | 04-09-2024 |
$1.31 | $1.2 | $1.31 | $1.32 | $1.2 | 40,063 | 04-08-2024 |
$1.234 | $1.3 | $1.234 | $1.32 | $1.2184 | 46,380 | 04-05-2024 |
$1.32 | $1.3669 | $1.32 | $1.49 | $1.296 | 151,964 | 04-04-2024 |
$1.424 | $1.415 | $1.424 | $1.476 | $1.4 | 49,079 | 04-03-2024 |
$1.39 | $1.3 | $1.39 | $1.42 | $1.3 | 80,750 | 04-02-2024 |
News, Short Squeeze, Breakout and More Instantly...
Mandatum Pankki Oyj Company Name:
MDNAF Stock Symbol:
OTCMKTS Market:
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a c...
Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity matched external control arm will also be presented as a poster TORONTO an...
100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2 MSI-H patients Durable stable disease (SD) in 3 melanoma patients for 6 to 18 months with co...